MINIMED GROUP INC

MMEDNASDAQ

🏆 #1059 by market capEarnings Sep 1US Equity

$453.41▼ $33.92 (−7.48%)

Simulated price

1h—

24h▼ 7.5%

7d▲ 2346.2%

14d▲ 2361.5%

30d▲ 2711.0%

1y—

🏦Market Cap

$5.56B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $446.80 – $457.98
52-Week Range: $10.65 – $20.48
Volume: $2.91B
Avg Volume: $2.62B
Shares Outstanding: 280.8M
Next Earnings: Sep 2, 2026

Fundamentals Snapshot

Annual Revenue: $3.10B
Last Q Revenue: $837M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own MMED

✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3.10B▲ +43.4% YoY

Gross Margin (TTM)

50.9%▲ +3.6% YoY

Operating Income (TTM)

$890M▲ +43.4% YoY

Free Cash Flow (TTM)

$608M▲ +43.4% YoY

About MINIMED GROUP INC

MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.

🦦